AstraZeneca (AZN LN) - AZD1222 is effective against COVID-19; met primary endpoint. COVID-19 average efficacy 70.4% when combining data from two dosing regimes. Two different dosage regimes: one has ~90% efficacy.

90% efficacy is the approach which commences with a half dose followed by a full dose administered at least one month apart (2,741 participants)
62% efficacy is the approach which has two full doses at least one month apart (8,895 participants)
"independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine."
Now immediately prepare the regulatory submission of data to global authorities
The vaccine can be stored, transported & handled at normal fridge conditions (2-8 degrees Celsius) for at least 6-months
Capacity of up to 3bln doses on a rolling basis in 2021
Well tolerated across both dosing regimes
Efficacy and safety data confirms it will be 'highly effective' against COVID-19
Vaccine will be affordable
Link to Release